Does CBD Make You Feel High? What a New Trial Found

What did the researchers test?

Researchers at the Centre hospitalier de l’Université de Montréal enrolled 70 healthy adults who used cannabis occasionally. In a triple-blind, randomized crossover design, each participant received five separate oral doses: placebo and 20, 50, 100, or 200 milligrams of synthetic CBD. The doses were taken immediately after a high-fat meal, and the order was randomized. Because every participant received every dose across different visits, each person served as their own comparison. Participants rated “pleasant drug effect” on a 0–100 visual scale at five points after dosing. Researchers also tracked other subjective effects, mood, anxiety, dissociation, blood pressure, heart rate, breathing rate, and adverse events.

What did the study find?

Only the 200 mg dose differed significantly from placebo on the primary outcome. On average, it produced a 12.8% higher peak “pleasant drug effect” score, with a 95% confidence interval from 3.8% to 21.8%. The researchers characterized the effect as slight but perceptible. The 20, 50, and 100 mg doses did not show a significant difference from placebo on that measure. All adverse events reported in the trial were mild or moderate.

Is CBD psychoactive, intoxicating, or both?

Those words are often used interchangeably, but they are not identical. “Psychoactive” broadly means that a substance can affect the brain, mood, or subjective experience. “Intoxicating” usually refers to a more substantial alteration that may impair judgment, coordination, perception, or performance. CBD can act on the body and brain without producing the characteristic intoxication associated with THC. This trial adds nuance: CBD may still create a subtle, dose-dependent subjective effect for some people. Calling CBD “non-intoxicating” remains more accurate than calling it inert.

Why the findings do not translate directly to every CBD product

The trial was designed to isolate CBD’s effects, not to recreate every real-world product or use pattern. Participants were healthy adults who used cannabis occasionally—results may differ in people with health conditions, heavier cannabis use, or different prior experience. Researchers tested a single dose at each visit, so the study cannot answer what happens with daily or long-term use. The product was synthetic CBD with controlled dosing; retail oils, gummies, and beverages may contain different amounts than their labels indicate and may include THC or contaminants. Every dose followed a high-fat meal, and food can affect oral CBD absorption, so the same labeled dose may not feel identical under different conditions. The primary outcome was a self-reported pleasant effect—it was not a comprehensive test of driving ability or workplace safety.

What should consumers take from this?

Dose matters, but the number on a label is not the whole story. Product quality, THC contamination, food, medications, individual biology, and repeated use can all change the experience. The FDA warns that CBD can interact with medications and may cause liver injury, drowsiness, gastrointestinal symptoms, or mood changes. Combining CBD with alcohol or other substances that slow brain activity can increase sedation. NCCIH also notes that over-the-counter CBD products may contain more or less CBD than the label states and may contain THC or other contaminants. For anyone taking prescription or over-the-counter medication, a pharmacist or health care professional can help screen for interactions. People who are pregnant or breastfeeding should avoid assuming that CBD is risk-free. And because a subtle effect may be unexpected at higher doses, it is prudent to avoid driving or safety-sensitive tasks until you know how a product affects you.

The takeaway

A well-controlled 2026 trial found that single oral CBD doses of 100 mg or less did not create a discernible subjective drug effect in healthy occasional cannabis users. At 200 mg, participants reported a small pleasant effect. That does not make CBD equivalent to THC, but it is a reminder that “non-intoxicating” should not be mistaken for “does nothing.” As CBD research becomes more dose-specific, consumers will be better served by precise language: what product, what dose, what route, what population, and what outcome?

Sources

1. Chester LA, et al. Acute behavioural effects of low-dose cannabidiol: A randomised crossover trial in healthy volunteers. Journal of Psychopharmacology (2026).
2. ClinicalTrials.gov. NCT05407285: A Study of Ingested Cannabidiol in Healthy Occasional Cannabis Users.
3. U.S. Food and Drug Administration. What You Need to Know About Products Containing Cannabis or Cannabis-Derived Compounds, Including CBD.
4. National Center for Complementary and Integrative Health. Cannabis (Marijuana) and Cannabinoids: What You Need To Know.